2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

1. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging
mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol.
2010;11:329-341.
2. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on
a theme. Oncogene. 2008;27:5497-5510.
3. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide
3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627-644.
4. Chalhoub N, Baker SJ. PTEN and the PI3-Kinase Pathway in Cancer.
Annu Rev Pathol Mech Disease. 2009;4:127-150.
5. Samuels Y, Diaz LA Jr., Schmidt-Kittler O, et al. Mutant PIK3CA
promotes cell growth and invasion of human cancer cells. Cancer Cell.
2005;7:561-573.
6. Vogt P, Gymnopolous M, Hart JR. PI 3-kinase and cancer: changing
accents. Curr Opin Genetics and Dev. 2009;19:1-6.
7. Wee S, Wiederschain D, Maira SM, et al. PTEN-deficient cancers depend
on PIK3CB. Proc Natl Acad Sci USA.2008;105:13057-13062.
8. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be
targeted in cancer? Curr Opin Cell Biol. 2009;21:199-208.
9. Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the
p110� isoform of PI3-kinase inhibits AML cell proliferation and survival and
increases the cytotoxic effects of VP16. Oncogene. 2006;25:6648-6659.
10. Shuttleworth SJ, Silva FA, Cecil AR, et al. Progress in the preclinical
discovery and clinical development of class I and dual class I/IV phosphoinositide
3-kinase (PI3K) inhibitors. Curr Med Chem. 2011;18:2686-2714.
11. Arcaro A, Wymann MP: Wortmannin is a potent phosphatidylinositol
3-kinase inhibitor. The role of phosphatidylinositol 3,4,5-trisphosphate in
neutrophil response. Biochem J. 1993;296:297-301.
12. Vlahos CJ, Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol
3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
(LY294002). J Biol Chem. 1994;269:5241-5248.
13. Workman P, Clarke PA, Raynaud FI, et al. Drugging the PI3 kinome:
from chemical tools to drugs in the clinic. Cancer Res. 2010;70:2146-2157.
14. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological
evaluation of pyrido[3�,2�:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3
kinase p110� inhibitors. Bioorg Med Chem Lett. 2007;17:2438-2442.
15. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization
of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res.
2007;67:5840-5850.
16. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological
evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as
novel PI3 kinase p110� inhibitors. Bioorg Med Chem. 2006;14:6847-6858.
17. Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent
inhibitors of class I phosphatidylinositide 3-kinases: From PI-103 through
PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009;8:1725-
1738.
e98
REFERENCES
WORKMAN AND CLARKE
18. Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1Hindazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-ylthieno[3,2d]pyrimidine
(GDC-0941) as a potent, selective, orally bioavailable
inhibitor of class I P13 kinase for the treatment of cancer. J Med Chem.
2008;51:5522-5532.
19. Sutherlin DP, Bao L, Berry M, et al. Discovery of a potent, selective,
and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian
target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of
cancer. J Med Chem. 2011;54:7579-7587.
20. Friedman L. GDC-0941, a potent selective orally bioavailable inhibitor
of class I PI3K. Proc American Assoc Cancer Res 2008;LB-110.
21. Yap TA, Workman P. Exploiting the cancer genome: Strategies for the
discovery and clinical development of targeted molecular therapeutics. Annu
Rev Pharmacol Toxicol. 2012;52:549-573.
22. Clarke PA, Workman P. Phosphatidylinositide-3-kinase inhibitors:
Addressing questions of isoform selectivity and pharmacodynamic/predictive
biomarkers in early clinical trials. J Clin Oncol. 2012;30:331-333.
23. Yap TA, Sandhu SK, Workman P, et al. Envisioning the future of early
anticancer drug development. Nat Rev Cancer. 2010;10:514-523.
24. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line
Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature. 2012;483:603-607.
25. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification
of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570-
575.
26. Workman P, Clarke PA, Al-Lazikani B. Personalized medicine: Patientpredictive
panel power. Cancer Cell. 2012; in press.
27. Guillard S, Clarke PA, Te Poele R, et al. Molecular pharmacology of
phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle. 2009;
8:443-453.
28. Hoeflich KP, Merchant M, Orr C, et al. Intermittent administration of
MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust
apoptosis and tumor growth inhibition. Cancer Res. 2012;72:210-219.
29. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback
regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate
cancer. Cancer Cell. 2011;19:575-586.
30. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of
BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid
tumors. J Clin Oncol. 2012;30:282-290.
31. Vasudevan KM, Arbie DA, Davies MA, et al. AKT-independent signaling
downstream of oncogenic PIK3CA mutations in human cancer. Cancer
Cell. 2009;16:21-32.
32. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic
Mutations in Cancer): A resource to investigate acquired mutations in human
cancer. Nucleic Acids Res. 2010;38:D652-D657.